Some providers featured on this site may compensate us. This may affect the order and placement of listings but does not influence our editorial ratings or reviews.
Treatments Hub

Verified prices

All verified prices
Eden logo

Eden Reviews

Compounded GLP-1 at one flat price - $99 semaglutide, $129 tirzepatide, every month

Last updated: Nov 15, 2026

9.7/10Exceptional - our rating

Medically reviewed on

Medical fact-checking by Francheska Capistrano, RMT, MPH

How we review

Visit Eden

We may earn a commission from links on this page - it never affects our rankings (how we stay objective).

The bottom line

Eden's case is simplicity: $99 for semaglutide and $129 for tirzepatide, the same every month and at every dose, with no membership and no plan to sign. If the lowest possible sticker price is your only criterion, welludr's $41 plan and embody's $49 month-to-month undercut it on semaglutide; if you want a flat price you can budget on, support that answers, and tirzepatide without a premium, Eden is one of the strongest no-commitment options we track.

Read the FDA warning-letter section below before you decide, check the eligibility and safety points with Eden's clinician at the assessment, and confirm shipping times at checkout.

Eden sells compounded semaglutide and tirzepatide at one flat, all-inclusive monthly price: $99/month for semaglutide and $129/month for tirzepatide, the same in month one, month two and every month after, at every dose - Eden's own pricing page puts it as 'the price you start with is the price you keep'. There is no membership, no annual plan and no long-term commitment; the clinical side is doctor-guided care with 24/7 human support, the medication is made in the US under what Eden describes as strict quality oversight, and sign-up is a free assessment that takes about three minutes with no insurance needed.

One thing to know: on June 8, 2026 the FDA sent Eden a warning letter (reference MARCS-CMS 728279) over two things on its website: product images whose labels carried the 'Eden' name, which the FDA said suggests Eden compounds the drugs when it does not, and a description of its pharmacies as 'FDA-licensed 503(a) outsourcing facilities', when the FDA does not license or approve compounding facilities. The FDA classed both as misbranding and gave Eden 15 business days to respond.

A warning letter is a regulatory finding about how the products were described; it is not evidence of a manufacturing defect, and it is not a clearance either, because compounded drugs are not evaluated by the FDA for safety, effectiveness or quality before they are sold. altRx received a letter dated the same day. We have not seen a published response or close-out as of November 15, 2026; the full letter and what it means are set out below.

What did the FDA's June 2026 warning letter to Eden say?

The letter is dated June 8, 2026, reference MARCS-CMS 728279, from the FDA's Office of Compounding Quality and Compliance to Eden Health International Inc. (read November 15, 2026). It makes two specific findings about Eden's website:

What the FDA foundWhy it matters
Pictures of the compounded semaglutide and tirzepatide products showed labels bearing the "Eden" name, which the FDA said "suggest[s] Eden is the compounder of those drugs when in fact it is not."A patient should be able to tell which pharmacy made the product. The FDA asked Eden to identify the entities that produce the products and to supply representative labeling.
The site described its pharmacies as "FDA-licensed 503(a) outsourcing facilities." The FDA stated that compounding facilities "are not 'FDA-approved' or 'FDA-licensed' entities."No compounding pharmacy or outsourcing facility holds FDA approval or an FDA licence; the phrase overstates the oversight a buyer is getting.

The FDA classed both as misbranding under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act and asked for a written response within 15 business days with corrective and preventive steps. altRx received a letter dated the same day.

Three things follow, and they pull in different directions. First, the letter contains no finding about the medication itself: no test result, no adverse-event report, no quality defect. Treating it as proof that Eden's products are unsafe would be wrong. Second, it is not insignificant: a warning letter is the FDA's formal notice that a company's conduct violates the law, and the two points it raises, who made the drug and how its oversight was described, are exactly the questions a compounded-GLP-1 buyer should be asking. Third, the letter is explicit that compounded products "have not been evaluated by FDA for safety, effectiveness, or quality before marketing." That applies to every compounded provider we rank, Eden included. As of November 15, 2026 we have not found a published response from Eden or an FDA close-out letter; we will update this section when either appears.

Who is eligible for Eden's program?

Eden's free assessment is reviewed by a clinician who decides whether compounded semaglutide or tirzepatide is appropriate and at what starting dose. Eligibility is a clinical judgment, not a single number. It depends on your body mass index, your medical history, any weight-related conditions, the contraindications below, the other medicines you take, and an individual assessment of risks and benefits.

For reference, the FDA-approved weight-management products that these compounded drugs are modelled on are indicated for adults with obesity (a BMI of 30 kg/m² or more) or with overweight (a BMI of 27 kg/m² or more) together with at least one weight-related condition such as high blood pressure, type 2 diabetes or abnormal cholesterol (Wegovy prescribing information, revised June 2026; Zepbound prescribing information, revised August 2026). Meeting a BMI threshold does not by itself make treatment appropriate, and falling just outside one does not by itself rule it out; that is what the clinician's review is for. Our BMI and eligibility check shows where you sit against the label criteria before you start the assessment.

What are the side effects and risks of compounded semaglutide and tirzepatide?

Compounded semaglutide and tirzepatide are not FDA-approved, so there is no label for the exact product Eden ships. The approved products' labels are the best available description of what to expect, and Eden's clinician should go through them with you.

Common effects. Nausea, vomiting, diarrhea, constipation and abdominal discomfort are the most frequently reported reactions with both drugs, most often when starting or after a dose increase; the labels allow a four-week pause before the next step when a dose is not tolerated.

Serious complications to know about. Acute pancreatitis; gallbladder disease, including gallstones; dehydration-associated acute kidney injury after prolonged vomiting or diarrhea; and severe gastrointestinal reactions. Persistent severe abdominal pain, an inability to keep fluids down, or signs of an allergic reaction (swelling of the face, lips or throat, trouble breathing) need urgent medical assessment.

Boxed warning and contraindications. Both semaglutide and tirzepatide carry a boxed warning for thyroid C-cell tumors, which were observed in rodents; whether this applies to humans is unknown. They are contraindicated in anyone with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), and in anyone who has had a serious allergic reaction to the drug.

Situations that need specific clinical consideration. Pregnancy and planned pregnancy (the Wegovy label advises stopping semaglutide at least two months before a planned pregnancy; tirzepatide can reduce the effectiveness of oral contraceptives, so a non-oral or added barrier method is advised for four weeks after starting and after each dose increase); severe gastroparesis, in which these medicines are not recommended; and concurrent glucose-lowering medicines such as insulin or a sulfonylurea, whose doses may need review because of the risk of low blood sugar.

Sources: Wegovy label (revised June 2026) and Zepbound label (revised August 2026), both read November 15, 2026. For how compounded doses are measured and the FDA's reports of dosing errors, see our guide to reading a compounded vial. This section is general information from the labels, not medical advice.

Key Features

  • Compounded semaglutide $99/month - same price at every dose
  • Compounded tirzepatide $129/month - same price at every dose
  • One all-inclusive price: no membership, no annual or long-term plans
  • Doctor-guided clinical care with 24/7 human support
  • Free 3-minute assessment; no insurance needed

Treatment Options

  • Compounded semaglutide (GLP-1) injection
  • Compounded tirzepatide (GLP-1 + GIP) injection
  • Doctor-guided dosing with ongoing clinical care
  • 24/7 human support

Pricing

Semaglutide

Monthly

Compounded semaglutide (GLP-1) injection

$99/month
  • Same price every month and at every dose
  • No membership or long-term plan
  • Doctor-guided care and 24/7 support included

Tirzepatide

Monthly

Compounded tirzepatide (GLP-1 + GIP) injection

$129/month
  • Same price every month and at every dose
  • No membership or long-term plan
  • Doctor-guided care and 24/7 support included

Eden charges $99/month for compounded semaglutide and $129/month for compounded tirzepatide. The price is flat: Eden's pricing table shows the same figure in month one, month two, month three and every month after, and the same at every dose, with no membership fee and no annual or long-term plan required.

That puts Eden's semaglutide alongside Medvi's $99 promotional rate and above the $41-$89 entry tier at welludr, embody and altRx - but Eden's figure is not a promotion with an end date, and its tirzepatide at $129 is among the lowest flat, no-commitment tirzepatide prices we track.

What we verified

Checked September 2026

Every line below was checked against Eden's own published pricing and plan information - not copied from other review sites. When we can't verify something, we leave it out rather than guess.

Semaglutide price
$99/month, flat every month and at every dose
Tirzepatide price
$129/month, flat every month and at every dose
Membership fee
None
Commitment
None - no annual or long-term plans required
Support
Doctor-guided care with 24/7 human support

How Eden Works

  1. 1
    Free · ~3 minutes

    Start the free assessment

    Answer the health questions online - no insurance needed.

  2. 2

    A doctor reviews your plan

    Doctor-guided clinical care decides whether semaglutide or tirzepatide is appropriate and sets your dose.

  3. 3
    Delivered to your door

    Receive your medication

    Compounded GLP-1 made in the US, shipped to you, with 24/7 human support throughout.

Pros

  • Flat pricing with no month-one trick: $99 semaglutide, $129 tirzepatide, every month, every dose
  • No membership, no annual plan, no long-term commitment
  • 24/7 human support and doctor-guided care included in the price
  • Low flat tirzepatide price for a no-commitment plan

Cons

  • Compounded only - no brand-name Ozempic, Wegovy or Zepbound option
  • Shipping speed is not stated on the pricing page we captured
  • No formal coaching or dietician layer described
  • FDA warning letter (June 8, 2026) citing the 'Eden' name on product labels and 'FDA-licensed' pharmacy wording as misbranding; no product-quality finding in the letter, and no public close-out as of November 2026

Interested in Eden?

Visit their site to check eligibility and current pricing.

Visit Eden

Who It's Best For

  • People who want one number that never changes, without committing to a plan
  • Anyone who values reachable, human support alongside the medication
  • Tirzepatide buyers who want a flat, no-commitment price

Final Verdict

Eden's case is simplicity: $99 for semaglutide and $129 for tirzepatide, the same every month and at every dose, with no membership and no plan to sign. If the lowest possible sticker price is your only criterion, welludr's $41 plan and embody's $49 month-to-month undercut it on semaglutide; if you want a flat price you can budget on, support that answers, and tirzepatide without a premium, Eden is one of the strongest no-commitment options we track.

Read the FDA warning-letter section below before you decide, check the eligibility and safety points with Eden's clinician at the assessment, and confirm shipping times at checkout.

Visit Eden

Eden Review: FAQs

Is Eden legit?

Eden sells compounded semaglutide and tirzepatide at one flat, all-inclusive monthly price: $99/month for semaglutide and $129/month for tirzepatide, the same in month one, month two and every month after, at every dose - Eden's own pricing page puts it as 'the price you start with is the price you keep'. There is no membership, no annual plan and no long-term commitment; the clinical side is doctor-guided care with 24/7 human support, the medication is made in the US under what Eden describes as strict quality oversight, and sign-up is a free assessment that takes about three minutes with no insurance needed. One thing to know: on June 8, 2026 the FDA sent Eden a warning letter (reference MARCS-CMS 728279) over two things on its website: product images whose labels carried the 'Eden' name, which the FDA said suggests Eden compounds the drugs when it does not, and a description of its pharmacies as 'FDA-licensed 503(a) outsourcing facilities', when the FDA does not license or approve compounding facilities. The FDA classed both as misbranding and gave Eden 15 business days to respond. A warning letter is a regulatory finding about how the products were described; it is not evidence of a manufacturing defect, and it is not a clearance either, because compounded drugs are not evaluated by the FDA for safety, effectiveness or quality before they are sold. altRx received a letter dated the same day. We have not seen a published response or close-out as of November 15, 2026; the full letter and what it means are set out below.

How much does Eden cost?

Eden charges $99/month for compounded semaglutide and $129/month for compounded tirzepatide. The price is flat: Eden's pricing table shows the same figure in month one, month two, month three and every month after, and the same at every dose, with no membership fee and no annual or long-term plan required. That puts Eden's semaglutide alongside Medvi's $99 promotional rate and above the $41-$89 entry tier at welludr, embody and altRx - but Eden's figure is not a promotion with an end date, and its tirzepatide at $129 is among the lowest flat, no-commitment tirzepatide prices we track.

What treatments does Eden offer?

Eden offers Compounded semaglutide (GLP-1) injection, Compounded tirzepatide (GLP-1 + GIP) injection, Doctor-guided dosing with ongoing clinical care, 24/7 human support.

Who is Eden best for?

Eden is best for People who want one number that never changes, without committing to a plan; Anyone who values reachable, human support alongside the medication; Tirzepatide buyers who want a flat, no-commitment price.

Is Eden worth it?

Eden's case is simplicity: $99 for semaglutide and $129 for tirzepatide, the same every month and at every dose, with no membership and no plan to sign. If the lowest possible sticker price is your only criterion, welludr's $41 plan and embody's $49 month-to-month undercut it on semaglutide; if you want a flat price you can budget on, support that answers, and tirzepatide without a premium, Eden is one of the strongest no-commitment options we track. Read the FDA warning-letter section below before you decide, check the eligibility and safety points with Eden's clinician at the assessment, and confirm shipping times at checkout.

Not sure if Eden is right for you?

Take our free quiz and get a personalized provider recommendation.

Find Your Match

Sources & methodology

We built this review of Eden from the provider'sown published pricing, plans and policies, cross-checked against regulatory and peer-reviewed medical references, and read alongside real customer feedback. Prices and plan details were verified against the provider's published information; we do not take providers' word for their own claims without checking.

Provider information

Pricing, plans, shipping and policies, checked against each provider's own site.

  • Eden - pricing, plans & policies as published on its own site

Provider data checked September 2026

Customer & community feedback

Third-party signals shown on this page and in our full reviews: public Reddit discussions and independent YouTube reviews. We report what these sources say - we never fold them into our own scores.

Medical & regulatory references

  1. 1.Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1 trial) - New England Journal of Medicine, 2021
  2. 2.Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1 trial) - New England Journal of Medicine, 2022
  3. 3.FDA Approves New Drug Treatment for Chronic Weight Management (semaglutide / Wegovy) - U.S. Food & Drug Administration, 2021
  4. 4.FDA Approves New Medication for Chronic Weight Management (tirzepatide / Zepbound) - U.S. Food & Drug Administration, 2023
  5. 5.FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss - U.S. Food & Drug Administration
  6. 6.Human Drug Compounding (503A pharmacy standards) - U.S. Food & Drug Administration
  7. 7.Semaglutide Injection - drug information - MedlinePlus, U.S. National Library of Medicine (NIH)

Last reviewed September 2026. We revisit comparisons when providers change their pricing or policies. This page is information only and is not medical advice - always consult a licensed clinician before starting treatment.

Medical disclaimer

This page is general information about GLP-1 weight-loss medications such as semaglutide and tirzepatide, published to help you compare services. It is not medical advice, it does not create a doctor-patient relationship, and it is not a substitute for a consultation with a licensed clinician who knows your history. Treatments Hub is not a medical provider, pharmacy or clinic and does not prescribe, sell or dispense medication. Do not start, stop or change any treatment because of something you read here, and do not delay seeking care; in an emergency call 911.

Semaglutide and tirzepatide carry an FDA boxed warning about thyroid C-cell tumours seen in rodents and are not for anyone with a personal or family history of medullary thyroid carcinoma or MEN 2, nor for use in pregnancy. Compounded versions sold by telehealth providers are prepared by state-licensed pharmacies and are not FDA-approved products. Where a review or post on this page mentions weight lost, that is one person's result and is not typical; results vary widely.

Medical and scientific statements on this site are checked against the sources linked on the page by our medical content reviewer, who does not choose providers or set prices. Prices, plans and customer reviews are each provider's published figures and customers' own words on the dates stated. We may earn a commission from provider links. The full medical and advertising disclaimer explains all of this in detail.

Sources & medical references

Treatment facts on this page are grounded in regulatory guidance and peer-reviewed research. Pricing and plan details come from each provider's published information. This content is for information only and is not medical advice - always consult a licensed clinician before starting treatment.

  1. 1.Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1 trial) - New England Journal of Medicine, 2021
  2. 2.Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1 trial) - New England Journal of Medicine, 2022
  3. 3.FDA Approves New Drug Treatment for Chronic Weight Management (semaglutide / Wegovy) - U.S. Food & Drug Administration, 2021
  4. 4.FDA Approves New Medication for Chronic Weight Management (tirzepatide / Zepbound) - U.S. Food & Drug Administration, 2023
  5. 5.FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss - U.S. Food & Drug Administration
  6. 6.Human Drug Compounding (503A pharmacy standards) - U.S. Food & Drug Administration
  7. 7.Semaglutide Injection - drug information - MedlinePlus, U.S. National Library of Medicine (NIH)